Search results for " patient"

showing 10 items of 3263 documents

Authors' Reply to “Lung Volume Reduction Surgery in Patients With Enphysema: the Spanish Experience

2005

medicine.medical_specialtybusiness.industryGeneral surgerymedicineIn patientGeneral MedicineLung volume reduction surgerybusinessSurgeryArchivos de Bronconeumología ((English Edition))
researchProduct

Breakthrough Cancer Pain: Ten Commandments

2016

The term "breakthrough cancer pain" (BTcP) was introduced about 25 years ago. Peaks of pain intensity reported in patients with cancer had been invariably examined in the past years, providing relevant information for a better knowledge of this phenomenon and its treatment. The aim of this critical review was to provide the golden rules, namely, the 10 commandments, for a correct diagnostic pathway of BTcP and a consequent personalized pharmacological treatment. These are as follows: 1) assessment of background analgesia, 2) drugs used for background analgesia, 3) BTcP is a frequent phenomenon, 4) characteristics of BTcP, 5) diagnosis of BTcP, 6) continuous assessment, 7) tailored pharmacol…

medicine.medical_specialtybusiness.industryHealth PolicyBreakthrough PainPublic Health Environmental and Occupational HealthAlternative medicineCancer PainPharmacological treatment03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisAnesthesiaHumansPain ManagementMedicineIn patientDosingbusinessCancer painIntensive care medicineRelevant information030217 neurology & neurosurgeryValue in Health
researchProduct

Limitations of nasal nitric oxide as a screening method of primary ciliary dyskinesia in childhood

2016

Introduction: Nasal nitric oxide (nNO) has been proposed as a screening tool for primary ciliary dyskinesia (PCD). However, there are no reference values by age in consensus guidelines. Objectives: 1) To analyze differences in nNO among a group of patients with PCD and healthy controls. 2) To determine the proportion of pediatric PCD patients with nNO values similar to healthy population. Methods: Determination of nNO by electrochemical system (NIOX Vario®) in patients with DCP (diagnosis confirmed by digital high speed videomicroscopy) and healthy controls (without asthma, rhinitis or atopic dermatitis), aged between 7 and 60 years. Results: 32 patients (17 children, 53.1%) and 32 controls…

medicine.medical_specialtybusiness.industryHealthy populationNo referenceAtopic dermatitismedicine.diseaseGastroenterologySurgeryNitric oxidechemistry.chemical_compoundchemistryInternal medicineotorhinolaryngologic diseasesmedicineScreening methodIn patientbusinessAsthmaPrimary ciliary dyskinesia5.2 Monitoring Airway Disease
researchProduct

P-34 The randomized, double-blind, placebo-controlled phase 3 trial KEYNOTE-975: Pembrolizumab vs placebo in patients with esophageal carcinoma recei…

2020

medicine.medical_specialtybusiness.industryHematologyDefinitive chemoradiotherapyPembrolizumabPlacebomedicine.diseaseGastroenterologyDouble blindOncologyInternal medicineCarcinomaMedicineIn patientbusinessAnnals of Oncology
researchProduct

Hepatocellular carcinoma: Diagnostic imaging criteria

2020

The diagnosis of hepatocellular carcinoma (HCC) can be reached noninvasively on imaging in patients at high risk as discussed in chapter “Hepatocellular carcinoma: Diagnostic Guidelines.” In this chapter, we describe the CT and MR imaging criteria more commonly used in the guidelines for the diagnosis and management of patients with HCC, including arterial phase hyperenhancement, washout, capsule, growth, and hypointensity on hepatobiliary phase MR imaging. The provided definitions are based on the latest version (v2018) of the liver imaging reporting and data system (LI-RADS) document (American College of Radiology 2018, https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-…

medicine.medical_specialtybusiness.industryHepatocellular carcinomamedicine.diseaseMr imagingHepatocellular carcinomamedicineHepatobiliary phaseMedical imagingIn patientRadiologybusinessSettore MED/36 - Diagnostica Per Immagini E RadioterapiaArterial phaseLiver imagingMRICT
researchProduct

The role of elevated growth hormone on the increased atherosclerosis in patients with acromegaly.

2012

medicine.medical_specialtybusiness.industryHuman Growth HormoneMEDLINEGrowth Hormone Atherosclerosis AcromegalyBioinformaticsmedicine.diseaseGrowth hormoneAtherosclerosisText miningEndocrinologyRisk FactorsInternal medicineAcromegalyAcromegalymedicineHumansIn patientInsulin ResistanceInsulin-Like Growth Factor ICardiology and Cardiovascular MedicinebusinessAngiology
researchProduct

SAT0136 Focus on Implementation of Cardiovascular Risk Factor Recording for Patients with Rheumatoid Arthritis in A Rheumatology Outpatient Clinic

2014

Objectives There is a need for implementing the knowledge of cardiovascular (CV) risk in patients with rheumatoid arthritis (RA) into clinical practice. Our aim was to evaluate CV risk factor (CVRF) recording in a rheumatology outpatient clinic (ROC), where the standard was annual CVRF recording. A second aim was to compare CVRF recording between a regular ROC (RegROC) and an arthritis clinic (AC), which consisted of a structured, team-based model. Methods In 2012, 1142 RA patients visited the ROC of the Hospital of Southern Norway. Of these 612 attended RegROC and 530 attended AC. We conducted a search in the patients9 hospital records to identify recording of CVRFs. Results CVRFs were rec…

medicine.medical_specialtybusiness.industryImmunologyArthritisOdds ratiomedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyRheumatologyBlood pressureRheumatologyInternal medicineRheumatoid arthritismedicinePhysical therapyImmunology and AllergyOutpatient clinicIn patientRisk factorbusinessAnnals of the Rheumatic Diseases
researchProduct

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity

2019

Background: Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening autoimmune thrombotic microangiopathy that involves abnormal processing of von-Willebrand factor (vWF) and results in multiple organ dysfunction. Although aTTP remains a very unpredictable disease, risk factors for death include older age, lactate dehydrogenase (LDH) levels >10x the upper limit of normal (ULN), and cerebral involvement (i.e., the French severity score) (Benhamou et al. Haematologica 2012;97:1181-1186). In addition, raised cardiac troponin-I (cTnI) levels of >2.5 µg/L have also been linked with a higher risk of mortality or refractoriness (Benhamou et al. J Thromb Haemost 2015;1…

medicine.medical_specialtybusiness.industryImmunologyCell BiologyHematologyBiochemistryTherapeutic immunosuppressionDisease severityInternal medicineSeverity of illnessmedicinePlatelet Count measurementThrombotic MicroangiopathiesIn patientCaplacizumabbusinessBlood
researchProduct

Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myelo…

2018

Abstract Introduction: Mutations localized in the tyrosine kinase domain activation loop of FLT3 (FLT3-TKD), representing point mutations in codon D835/I836 and rarely deletions of codon I836, induce constitutive tyrosine phosphorylation and activation of the receptor tyrosine kinase similarly to FLT3 internal tandem duplication (ITD) mutations. However, the prognostic role of FLT3-TKD in AML, particularly in the presence of NPM1 mutations, is not well established. The phase 3 RATIFY trial [NCT00651261; Stone et al. N Engl J Med. 2017] showed that in combination with standard chemotherapy, midostaurin (PKC412) improved survival outcomes across all 3 FLT3 stratification subgroups (ITD high a…

medicine.medical_specialtybusiness.industryImmunologyComplete remissionImproved survivalCell BiologyHematologyNewly diagnosedPlaceboBiochemistryConsolidation therapy03 medical and health sciencesNPM1 Mutationchemistry.chemical_compound0302 clinical medicinechemistry030220 oncology & carcinogenesisFamily medicineMedicineIn patientMidostaurinbusiness030215 immunologyBlood
researchProduct

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Mul…

2019

Continuous treatment with lenalidomide (R) and dexamethasone (d) is a standard of care for multiple myeloma (MM) patients (pts) not candidates for autologous stem cell transplantation (ASCT). As previously reported, the addition of Clarithromycin (C) to Rd has proven to be safe and effective, and case-control analyses suggested a significant additive value with the combination. C optimizes the therapeutic effect of glucocorticoids by increasing the area under the curve, has immunomodulatory effects and may have direct antineoplastic properties. However, there are not randomized phase III trials confirming these results. GEM-Claridex in an open, randomized, phase III trial for untreated new…

medicine.medical_specialtybusiness.industryImmunologyDisease progressionCell BiologyHematologymedicine.diseaseBiochemistrylaw.inventionTransplantationClinical trialAutologous stem-cell transplantationRandomized controlled triallawInternal medicinemedicineIn patientbusinessMultiple myelomaLenalidomidemedicine.drugBlood
researchProduct